3.31

3.44% 0.11

After Hours: 3.24 -0.07 -2.11%

Arbutus Biopharma Corp (ABUS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arbutus Biopharma Corp stock is traded at $3.31, with a volume of 592.72K. It is up +3.44% in the last 24 hours and down -2.36% over the past month. Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Previous Close:

$3.20

Open:

$3.2

24h Volume:

592.72K

Relative Volume:

0.73

Market Cap:

$624.87M

Revenue:

$12.99M

Net Income/Loss:

$-74.39M

P/E Ratio:

-7.5227

EPS:

-0.44

Net Cash Flow:

$-78.92M

1W Performance:

+3.76%

1M Performance:

-2.36%

6M Performance:

-20.05%

1Y Performance:

+32.40%

1-Day Range:

$3.20

$3.32

1-Week Range:

$3.16

$3.505

52-Week Range:

$2.30

$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name

Arbutus Biopharma Corp

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

604-419-3200

Address

701 VETERANS CIRCLE, WARMINSTER, PA

Employee

Twitter

@arbutusbio

Next Earnings Date

2025-03-19

Latest SEC Filings

ABUS's Discussions on Twitter

Compare ABUS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABUS Arbutus Biopharma Corp	3.31	624.87M	12.99M	-74.39M	-78.92M	-0.44
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Initiated	Jefferies	Hold
Dec-17-20	Initiated	H.C. Wainwright	Buy
Jul-27-20	Resumed	JMP Securities	Mkt Outperform
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-20-20	Initiated	Robert W. Baird	Outperform
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Oct-07-19	Reiterated	B. Riley FBR	Buy
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral
Oct-12-18	Reiterated	Chardan Capital Markets	Buy
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Mar-19-18	Resumed	Chardan Capital Markets	Buy
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-01-17	Reiterated	Wedbush	Outperform
Dec-13-16	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-30-16	Upgrade	Chardan Capital Markets	Neutral → Buy

View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

Mar 08, 2025

FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World

Mar 08, 2025

Mar 07, 2025

Are Arbutus Biopharma Corp’shares a good deal? - US Post News

Mar 07, 2025

Mar 05, 2025

Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World

Mar 05, 2025

Mar 04, 2025

Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360

Mar 04, 2025

Mar 03, 2025

Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq

Mar 03, 2025

Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire

Mar 03, 2025

Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan

Mar 03, 2025

Feb 28, 2025

Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Feb 28, 2025

Arbutus Biopharma (NASDAQ:ABUS) Lowered to “Sell” Rating by StockNews.com - Defense World

Feb 26, 2025

Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo

Feb 26, 2025

Feb 25, 2025

Lindsay Androski named CEO of Arbutus - BioCentury

Feb 25, 2025

Arbutus Biopharma appoints new CEO and reshapes board - Investing.com

Feb 25, 2025

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - The Manila Times

Feb 25, 2025

Feb 24, 2025

Arbutus Biopharma Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Feb 24, 2025

Feb 20, 2025

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool

Feb 20, 2025

Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN

Feb 20, 2025

Feb 12, 2025

The Hidden Gem in Nasdaq’s Under $5 Club: Is Arbutus Biopharma the Next Big Thing? - Jomfruland.net

Feb 12, 2025

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? - MSN

Feb 12, 2025

Feb 11, 2025

Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR

Feb 11, 2025

10 Best Nasdaq Stocks Under $5 to Buy - Insider Monkey

Feb 11, 2025

Feb 08, 2025

SG Americas Securities LLC Purchases 16,250 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Feb 08, 2025

Feb 06, 2025